Claritin

Quick links to important sections

Claritin

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Claritin

Property Description
Active Ingredient Loratadine
Form Tablet, Syrup, Oral Disintegrating Tablet (ODT)
Pharmacological Class Second-generation antihistamine; Selective H1-receptor antagonist
General Purpose Inhibits histamine action
Origin Synthetic compound (Piperidine derivative)

What is the Core Identity and Composition of Claritin?

Claritin is the widely recognized trade name for the drug entity containing the active ingredient Loratadine. Loratadine is a synthetic compound classified chemically as a Piperidine derivative, and is typically sold as an Over-the-Counter (OTC) monotherapy product when not combined with other active agents. Loratadine is metabolized to its active compound, Desloratadine, which contributes significantly to its therapeutic effect, confirming its function for systemic treatment via the oral route of administration.


Why is Loratadine Classified as a Second-Generation Antihistamine?

Loratadine is definitively classified as a second-generation antihistamine and functions specifically as a selective peripheral H1-receptor antagonist. This means the drug is designed to inhibit the action of histamine by blocking its attachment to H1 receptors primarily located outside the central nervous system. This selective blockade is clinically recognized for contributing to the drug's generally non-sedating profile compared to older H1 antagonists.

The drug is a long-acting compound; H1 antagonists, including Loratadine, provide effective, sustained inhibition of histamine-related responses for a full 24-hour effect period. This confirms that a single daily dose can support continuous, systemic symptom management.


What Forms of Claritin Are Available for Systemic Treatment?

Claritin is available in multiple dosage form(s) intended for oral intake, including the standard tablet and the liquid syrup formulations. Specialized presentations also exist, such as the chewable tablet and the oral disintegrating tablet (ODT). The availability of the liquid syrup formulation, for instance, specifically caters to the pediatric patient group, simplifying administration for children. The primary function of all these forms remains consistent: to serve as a long-acting inhibitor of histamine action.

Regulatory References

  1. Loratadine - LiverTox - NCBI Bookshelf

What side effects are possible with Claritin?

Possible Side Effects and Safety Information

The official safety profile for Claritin (loratadine) is established through regulatory classification of adverse reactions documented in clinical trials and during post-marketing surveillance.


Adverse Reaction Categories

Adverse reactions are organized by frequency, reflecting their rate of occurrence in regulatory documents. The most Common adverse reactions reported include headache, somnolence (sleepiness), fatigue, and dry mouth.

Very Rare reactions are those reported in post-marketing experience. These are typically serious in nature and include hypersensitivity reactions (e.g., anaphylaxis, angioedema), convulsion (seizures), tachycardia (fast heart rate), palpitation, nausea, vomiting, and abnormal hepatic function (liver issues). Other very rare effects involve the nervous, cardiac, gastrointestinal, and skin systems, such as dizziness, rash, and alopecia (hair loss).


Safety Restrictions and Limitations

Regulatory documents define specific populations and circumstances that require caution or limitation of use:

  • Organ Impairment: Caution is advised in patients with severe hepatic impairment (severe liver disease), as reduced clearance of the drug may occur. Caution is also advised in individuals with renal impairment (kidney disease).
  • Interactions: Caution is necessary when the medicine is co-administered with other drugs that are known to inhibit hepatic metabolism (e.g., ketoconazole, erythromycin, cimetidine).
  • Procedures: The medicine should be discontinued approximately two days before performing any skin testing procedures. This restriction is necessary because the drug may prevent or diminish the expected positive reactions to the test indicators.
  • Pediatric Use: The use of the medicine is typically contraindicated in children under 6 years of age.

Regulatory Safety Summary

This structure ensures transparency by distinguishing frequent, often manageable side effects from rare, potentially severe events, and by outlining specific limitations for patients with pre-existing conditions or those undergoing specific medical procedures.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation strictly outlines the manifestations and required emergency actions in the event of a Loratadine (Claritin) overdose.

Documented Overdose Manifestations and Risks

Feature Regulatory Documentation Statement
Documented Symptoms Overdose may present with somnolence (drowsiness), headache, and tachycardia (rapid heart rate).
Serious Risks Potential for significant toxicity exists, including the risk of cardiac arrhythmias and QT-interval prolongation, especially with high exposures.
High-Risk Groups Children and the elderly may be more susceptible to severe manifestations. Individuals with hepatic or renal impairment should note potential heightened sensitivity.

Mandated Emergency Actions

Immediate medical attention is required in all cases of suspected overdose. The official regulatory guidance instructs individuals to seek immediate medical attention or contact a Poison Control Center right away.

Treatment management is symptomatic and supportive, as no specific antidote is known for Loratadine overdose. Due to the risk of cardiotoxicity, continuous cardiac monitoring (e.g., ECG) is a necessary part of the management protocol, along with considering procedures such as the administration of activated charcoal or gastric lavage in a clinical setting.

Therapeutic Uses of Claritin

What Claritin Treats: Main Uses and Benefits

Loratadine is primarily used to provide systemic relief from the hallmark symptoms of allergic rhinitis, commonly known as hay fever, which can be either seasonal or perennial. It is commonly used to help with the cluster of symptoms associated with these conditions, including persistent sneezing, runny nose, nasal and throat itching, and accompanying itchy, watery eyes. This application is relevant in clinical settings marked by heightened distress due to environmental triggers, offering support that generally helps ease the overall symptom burden for sustained support.

Quick Fact: Support for Histamine-Driven Discomfort

The medication is also a commonly applied therapy for managing histamine-mediated skin manifestations such as hives (urticaria) and generalized skin itching (pruritus). The conditions for which this medication is commonly applied include allergic rhinitis, hay fever, seasonal allergies, perennial allergies, hives, and pruritus. This generally provides a key therapeutic benefit through its long-lasting profile, which is valuable for patients who require sustained support and is generally less likely to cause noticeable interference with alertness, helping to maintain functional balance.

“The long-acting, non-sedating profile generally assists with maintaining functional balance during episodes of heightened symptoms.”

Regulatory References

  1. NIH MedlinePlus Drug Information on Loratadine

Eligibility and Restrictions for Use

Who Can and Cannot Use Claritin?


Eligibility Scope

Classification Eligible Population Restriction/Exclusion
Allowed (Age Groups) Adults, Adolescents, and Children ≥ 6 years (standard tablets); Children 2 to 5 years (liquid/chewable forms). Children under 2 years of age (Use is generally excluded as safety is not established by regulators).
Contraindicated N/A Individuals with known hypersensitivity to loratadine, desloratadine, or any component in the formulation.
Conditional Use Patients with severe hepatic impairment or severe renal impairment (GFR < 30 mL/min). Requires a formally adjusted dosing interval due to reduced drug clearance.
Reproductive Status N/A Lactation is not recommended (excreted in breast milk). Use during pregnancy is advised to be avoided as a precautionary measure.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

  • Contraindicated: Hypersensitivity
  • Conditional/Restricted Use: Severe Organ Impairment, Lactation
  • Not Established: Children under 2 years

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define who can and cannot use Loratadine by establishing an absolute contraindication based on known allergy and setting minimum age thresholds for use. Eligibility is formally limited when the body's ability to clear the drug is reduced, such as in cases of severe liver or kidney impairment, requiring a modified dosing frequency. These rules strictly regulate the population scope to those with an established safety profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents identify that loratadine (the active ingredient in Claritin) is metabolized predominantly by the liver enzymes Cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, Cytochrome P450 2D6 (CYP2D6). Therefore, medicines that inhibit these enzymes can significantly alter the concentration of loratadine in the body.


Interacting Agents (Examples) Mechanistic Basis Regulatory Implication
Ketoconazole (Antifungal) Potent CYP3A4 inhibition, leading to substantially increased loratadine plasma concentrations. Pharmacokinetic interaction observed.
Erythromycin (Antibiotic) CYP3A4 inhibition, leading to substantially increased loratadine plasma concentrations. Pharmacokinetic interaction observed.
Cimetidine (H2 Blocker) Inhibition of both CYP3A4 and CYP2D6, leading to increased loratadine plasma concentrations. Pharmacokinetic interaction observed.

Official studies using these specific enzyme inhibitors have shown that co-administration substantially increases the plasma concentration of loratadine and its active metabolite. This pharmacokinetic change is the principal documented interaction, although controlled clinical studies have not reported clinically significant changes in the overall safety profile when loratadine is co-administered with these agents at therapeutic doses. Use in patients with hepatic or renal impairment may require caution as these conditions can also affect the clearance of loratadine and its metabolites.

Mechanism of Action

The mechanism of action for Claritin (loratadine) is centered on modulating specific receptor-mediated signaling pathways. The primary action is exerted through its classification as an inverse agonist or antagonist at peripheral histamine H1 receptors. This interaction blocks the binding of the endogenous mediator histamine** to these receptors on target cells, including those in vascular and smooth muscle tissue. This early molecular step interrupts the histamine-induced signaling cascade, thereby inhibiting the resulting cellular effects associated with increased histamine concentration.

Beyond primary receptor engagement, loratadine and its active metabolite, desloratadine, influence secondary signaling pathways. They engage mechanisms that inhibit signaling sequences associated with inflammation, such as those involving the NF-kappa B pathway, contributing to regulated states within targeted molecular processes. Due to the compound's low lipophilicity, it exhibits high selectivity for peripheral H1 receptors, restricting its passage across the blood-brain barrier and limiting central system engagement.

Dosage and Administration Information

Official Administration Instructions

Claritin (loratadine) is an oral medication taken once daily. The official instructions for its use detail the dose amount, frequency, and maximum daily limit, with special provisions for children and individuals with certain health conditions.


Dosage and Frequency

Population Recommended Dose (Loratadine) Frequency Maximum Limit (24 Hours)
Adults and Children 6 years and over 10 mg (one tablet or two teaspoonfuls of syrup) Once daily 10 mg
Children 2 to under 6 years of age 5 mg (one teaspoonful of syrup or one 5 mg chewable tablet) Once daily 5 mg
Children under 2 years of age Ask a doctor Ask a doctor Ask a doctor

Special Administration Rules

  • Patients with Liver or Kidney Disease: Individuals with hepatic or renal impairment should consult a doctor, as a dose adjustment (often 10 mg every other day) may be necessary to prevent accumulation of the drug.
  • Administration Time: The medicine may be taken with or without food.
  • Maximum Dose: Do not take more than the directed dose in a 24-hour period.

Form-Specific Instructions

  • Rapidly-Disintegrating Tablets (RediTabs): Place the tablet on the tongue and allow it to dissolve completely in the mouth with or without water. Use dry hands to peel back the foil packaging and remove the tablet just before use. Do not push the tablet through the foil.
  • Chewable Tablets: Must be thoroughly chewed or crushed before swallowing.

Missed Dose

If a dose is missed, take it as soon as you remember. If it is almost time for the next scheduled dose, skip the missed dose and continue the regular dosing schedule. Do not take a double dose to make up for a missed one.

Recent Clinical Evidence

Research evidence / Overview of studies for Claritin (Loratadine)

Research for Seasonal Allergic Rhinitis

Research examined how the agent was studied for individuals experiencing conditions characterized by fluctuating or episodic manifestations, often referred to as hay fever. These studies were relevant in trials assessing short-term or episodic symptom patterns related to seasonal changes. The primary goal of this research was to monitor changes in outcomes related to physical discomfort, such as sneezing, itching, or a runny nose, when the agent was observed in these research scenarios.

Findings describe patterns observed in the studies related to outcomes related to physical discomfort. Research describes patterns related to temporary physiological changes that were monitored during the study period. Data show patterns related to outcomes reflecting daily functioning or activity level that were monitored. These studies help show what has been observed so far in groups with these specific, time-limited symptoms.

However, the evidence quality varies across studies, and follow-up durations were limited. Research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes. Data for certain populations, such as very young children, remain insufficient, and long-term effects are not fully established given the seasonal nature of the studies.

Research for Perennial Allergic Rhinitis

Studies for perennial (year-round) allergic rhinitis involve research contexts with varying symptom burdens because the condition is present continuously, unlike seasonal allergies. This research was evaluated in observational settings evaluating daily-life functioning and studies monitored patient-reported outcomes describing perceived discomfort that can persist over many months.

Studies report how symptoms evolved in the observed populations over defined time intervals, often focusing on outcomes related to systemic or functional imbalance. Studies explored outcomes linked to inflammatory or irritative states and monitored associated patterns of change.

Despite these findings, comparative evidence is lacking in many instances, meaning it is often uncertain how the observed patterns differ from other agents. Evidence is limited concerning use over multiple years, and findings indicate that certainty remains low for long-term or consistent changes in symptoms.

Research for Chronic Idiopathic Urticaria

The agent was studied for conditions involving periods of heightened symptoms, specifically long-term hives where the cause is unknown (idiopathic). This research explored outcomes capturing phases of heightened symptom activity and used in studies examining symptom intensity or variability. The research scenario often involved studies conducted during periods of increased symptom activity.

Findings help contextualize how patients reported their experience related to outcomes monitoring physiological strain or stress associated with these recurring episodes.

It is important to note that the results apply only to the populations studied, and sample sizes were modest in some of the pivotal trials. Evidence highlights what is known—and what is still uncertain—especially regarding symptoms that vary greatly in intensity. Subgroup findings are uncertain, and long-term effects are not fully established for use over many years in these conditions.

Key Studies & References

  1. H1-antihistamines for chronic spontaneous urticaria: an abridged Cochrane Systematic Review
  2. Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis

Frequently Asked Questions (FAQ)

Common questions about Claritin (FAQ)

Q: How long does it take for Claritin to start working?

Studies examined by official sources indicate that the antihistaminic effect has been observed to begin relatively quickly, typically within one to three hours after taking the medicine. The maximum effect has been observed in studies to be reached between 8 and 12 hours.


Q: How long does the effect of Claritin last?

The medicine is classified as a long-acting compound. Studies indicate that the drug's sustained action lasts in excess of 24 hours, which is a core property of its pharmacological classification.


Q: Is it possible to take Claritin every day for a long time?

Official regulatory documents do not specify an explicit time limitation for how long the drug can be taken daily. The research evidence includes studies for use in continuous conditions, such as chronic hives. Furthermore, research indicates that the medicine does not show a loss of effectiveness over time in humans.


Q: Does Claritin interact with alcohol?

According to official regulatory information, alcohol has not been found to interact with the active ingredient in Claritin (loratadine). The primary documented interactions are with specific liver enzyme inhibitors.


Q: Does Claritin cause weight gain?

Official safety documents establish a profile of common and very rare adverse reactions. Weight gain is not listed as a documented side effect in those categories.


Q: Is there a non-drowsy version of Claritin?

The drug is officially labeled as 'Non-Drowsy' when used according to directions. However, the official safety profile documents list somnolence (sleepiness) as a commonly reported adverse reaction. This possibility is reflected in the official safety profile.


Q: What is the difference between Claritin and Claritin-D?

Claritin-D is a combination medicine. It contains the antihistamine loratadine (found in Claritin) plus the active ingredient pseudoephedrine. Pseudoephedrine is an oral decongestant used to help relieve nasal and sinus congestion, which makes it a separate product.


Q: What happens if you take more Claritin than the recommended amount?

Official instructions warn against taking more than the directed dose, stating that exceeding the dose may cause increased drowsiness. The label advises seeking immediate medical help or contacting a Poison Control Center right away in the event of an overdose.


Q: Is Claritin safe to use during pregnancy (informational question)?

The official regulatory position is that use during pregnancy is advised to be avoided as a precautionary measure. The official labeling instructs pregnant individuals to consult a healthcare professional before use.


Q: Can I take Claritin if I am breastfeeding (informational question)?

Use while breastfeeding is not recommended in official documents. This recommendation is based on the fact that the active drug is known to be excreted into breast milk.


Q: What is the difference between Claritin and Zyrtec?

The two medicines contain different active ingredients. Claritin's active ingredient is loratadine, while Zyrtec's active ingredient is cetirizine. Both are classified by regulators as second-generation antihistamines.


Q: Is Claritin considered a steroid?

No, Claritin is not classified as a steroid. Official documents define it by its function as a second-generation antihistamine and a selective H1-receptor antagonist.


Q: What is Claritin used for besides allergies?

Official research evidence supports its use for symptoms related to seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis (year-round allergies). It is also studied for use in chronic idiopathic urticaria (long-term hives where the cause is unknown).


Q: Is it true that Claritin's effectiveness decreases over time?

Official research evidence does not support a decrease in effectiveness over time. Studies indicate that the concentration of the drug in the body is not altered by the duration of treatment, and no loss of effectiveness is shown in humans.


Q: What is the time-release technology mentioned in some Claritin products?

The time-release technology is typically found in Claritin-D products. These are described as containing an active ingredient in a 24-hour extended-release tablet formulation, which is designed to release medicine over a longer period.


Q: Why is Claritin available over-the-counter?

The medicine is available over-the-counter (OTC) because the FDA formally determined that the product's safety and effectiveness profile allows for it to be used appropriately by consumers without the direct supervision of a healthcare professional.


Q: Is Claritin gluten-free?

Official labeling lists the inactive ingredients, which include lactose monohydrate, magnesium stearate, and starch (maize). The core FDA labeling does not include a formal 'Gluten-free' status statement.


Q: Is it normal to feel a bit restless after taking Claritin?

While not listed as a common reaction in the core US safety documents, some international regulatory sources describe feeling nervous or dizziness as potential adverse reactions.


Q: Does Claritin have an impact on cognitive function or memory?

As a second-generation antihistamine, the drug is associated with a reduced effect on the central nervous system due to its limited ability to cross the blood-brain barrier. This is consistent with its official classification.


Q: Do studies suggest Claritin helps with watery eyes?

Yes, the official uses for the medicine include the temporary relief of symptoms associated with hay fever and other upper respiratory allergies, such as itchy, watery eyes. This is explicitly mentioned in the official uses section.

How should Claritin be stored and disposed of?

The storage and disposal of Claritin (loratadine) must adhere strictly to the conditions set forth in official regulatory labeling.

Official Storage Requirements

Formulation Required Storage Temperature Environmental Protection
Tablets 20 to 25 C (68 to 77 F) Protect from excessive moisture
Syrup 2 and 25 C (36 and 77 F) Keep from freezing

The medicine must be kept out of reach of children. The product must not be used if the container seal is missing, open, or broken, or if the individual blister unit is torn.

Disposal

Official labeling instructs users to discard outdated medicine or medicine no longer needed. The disposal of unused product must be completed according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Claritin found in:

A-Z Index: